Shandong Sito Bio-technology Co., Ltd. (300583.SZ)
CNY 22.9
(-0.82%)
CNY 22.9
(-0.82%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.27 Billion CNY | -2.46% |
| 2022 | 1.31 Billion CNY | 9.1% |
| 2021 | 1.2 Billion CNY | 31.7% |
| 2020 | 913.18 Million CNY | -5.45% |
| 2019 | 965.8 Million CNY | -8.22% |
| 2018 | 1.05 Billion CNY | 33.95% |
| 2017 | 785.56 Million CNY | 38.24% |
| 2016 | 568.24 Million CNY | -14.95% |
| 2015 | 668.16 Million CNY | 28.24% |
| 2014 | 521.01 Million CNY | 83.72% |
| 2013 | 283.58 Million CNY | 2470.7% |
| 2012 | 11.03 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 244.39 Million CNY | -31.46% |
| 2024 Q3 | 198.38 Million CNY | -38.44% |
| 2024 Q2 | 322.25 Million CNY | 31.86% |
| 2023 FY | 1.27 Billion CNY | -2.46% |
| 2023 Q4 | 356.55 Million CNY | 37.36% |
| 2023 Q1 | 334.78 Million CNY | -11.7% |
| 2023 Q2 | 328.86 Million CNY | -1.77% |
| 2023 Q3 | 259.56 Million CNY | -21.07% |
| 2022 Q2 | 382.59 Million CNY | 50.84% |
| 2022 FY | 1.31 Billion CNY | 9.1% |
| 2022 Q4 | 379.15 Million CNY | 27.79% |
| 2022 Q3 | 296.7 Million CNY | -22.45% |
| 2022 Q1 | 253.64 Million CNY | -20.87% |
| 2021 FY | 1.2 Billion CNY | 31.7% |
| 2021 Q2 | 351.23 Million CNY | 28.95% |
| 2021 Q1 | 272.37 Million CNY | 44.74% |
| 2021 Q3 | 258.46 Million CNY | -26.41% |
| 2021 Q4 | 320.54 Million CNY | 24.02% |
| 2020 Q3 | 232.08 Million CNY | -14.28% |
| 2020 Q1 | 222.17 Million CNY | 24.11% |
| 2020 FY | 913.18 Million CNY | -5.45% |
| 2020 Q2 | 270.74 Million CNY | 21.86% |
| 2020 Q4 | 188.17 Million CNY | -18.92% |
| 2019 Q4 | 179 Million CNY | -13.52% |
| 2019 FY | 965.8 Million CNY | -8.22% |
| 2019 Q3 | 206.99 Million CNY | -29.23% |
| 2019 Q1 | 287.32 Million CNY | 40.06% |
| 2019 Q2 | 292.47 Million CNY | 1.79% |
| 2018 Q1 | 240.68 Million CNY | -14.74% |
| 2018 FY | 1.05 Billion CNY | 33.95% |
| 2018 Q4 | 205.13 Million CNY | -28.4% |
| 2018 Q3 | 286.5 Million CNY | -10.45% |
| 2018 Q2 | 319.95 Million CNY | 32.94% |
| 2017 Q3 | 197.43 Million CNY | -2.62% |
| 2017 Q1 | 103.07 Million CNY | -44.84% |
| 2017 Q4 | 282.3 Million CNY | 42.98% |
| 2017 Q2 | 202.75 Million CNY | 96.72% |
| 2017 FY | 785.56 Million CNY | 38.24% |
| 2016 Q3 | 118.03 Million CNY | -45.41% |
| 2016 FY | 568.24 Million CNY | -14.95% |
| 2016 Q2 | 216.21 Million CNY | 358.57% |
| 2016 Q4 | 186.85 Million CNY | 58.31% |
| 2016 Q1 | 47.14 Million CNY | -73.91% |
| 2015 Q4 | 180.74 Million CNY | 0.0% |
| 2015 FY | 668.16 Million CNY | 28.24% |
| 2014 FY | 521.01 Million CNY | 83.72% |
| 2013 FY | 283.58 Million CNY | 2470.7% |
| 2012 FY | 11.03 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Beijing Scitop Bio-tech Co., Ltd. | 299.24 Million CNY | -327.675% |
| Lifecome Biochemistry Co.,Ltd. | 507 Million CNY | -152.42% |
| Chengdu Kanghua Biological Products Co., Ltd. | 1.56 Billion CNY | 18.362% |
| NanHua Bio-medicine Co., Ltd | 136.79 Million CNY | -835.576% |
| Porton Pharma Solutions Ltd. | 3.66 Billion CNY | 65.104% |
| Zhejiang Wecome Pharmaceutical Company Limited | 519.62 Million CNY | -146.292% |
| Guangdong VTR Bio-Tech Co., Ltd. | 796.02 Million CNY | -60.772% |